The first patient has been recruited in an exploratory Phase Ib clinical trial of Targovax’s second product from its RAS-peptide immunotherapy platform, TG02. In the open-label, non-randomised trial — to
Tag "Targovax"
Targovax has recruited its first patient in a Phase Ib trial for its new cancer vaccine TG02 targeting mutations of the RAS gene. Mutations of the RAS gene disrupt normal cell
Advertisements
